1. Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178–88.
2. US Department of Health an Human Services. New Drug Approval. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209637s000ltr.pdf. Accessed 15 Dec 2017.
3. Novo Nordisk. Ozempic® (semaglutide) approved in the US [media release]. 5 Dec. 2017. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2154210.html.
4. Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use: US prescribing Information. 2017. http://www.novo-pi.com/ozempic.pdf. www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Accessed 2017.
5. European Medicines Agency. Ozempic (semaglutide): opinion. 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004174/smops/Positive/human_smop_001235.jsp&mid=WC0b01ac058001d127. Accessed 20 Dec 2017.